NanoVibronix, Inc. (NAOV)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Revenues | 494 | 1,025 | 376 | 817 |
| Cost of revenues | 529 | 656 | 243 | 389 |
| Gross profit (loss) | -35 | 369 | 133 | 428 |
| Selling and marketing | 717 | 349 | 181 | 199 |
| Research and development | 972 | 530 | 249 | 187 |
| General and administrative | 2,252 | 1,342 | 673 | 716 |
| Total operating expenses | 3,941 | 2,221 | 1,103 | 1,102 |
| Loss from operations | -3,976 | -1,852 | -970 | -674 |
| Interest expense | 144 | 53 | 33 | 34 |
| Financial income, net | 211 | -10 | 8 | 24 |
| Change in fair value of convertible note | - | 58 | - | - |
| Warrant modification expense | - | 623 | - | - |
| Loss before taxes on income | -3,909 | -2,480 | -995 | -684 |
| Income tax expense | 62 | 15 | 3 | 4 |
| Net loss | -3,971 | -2,495 | -998 | -688 |
| Dividend on convertible preferred series x | 344 | - | - | - |
| Deemed contribution | -3,815 | - | - | - |
| Net loss available to common stockholders | -500 | -2,495 | -998 | -688 |
| Basic net loss available for holders of common stock | -1.03 | - | -0.36 | -0.25 |
| Diluted net loss available for holders of common stock | -1.03 | 3.98 | -0.36 | -0.25 |
| Weighted average common stock outstanding, basic | 484,566 | 626,150 | 2,803,181 | 2,784,353 |
| Weighted average common stock outstanding, diluted | 484,566 | 626,150 | 2,803,181 | 2,784,353 |